Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAkari Therapeutics raises $5.5M in dilutive private placement with warrants
Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Company sold 1.47M ADSs at $3.74/unit plus three series of warrants (H, I, J) exercisable at $3.74, creating significant potential dilution if all warrants are exercised by investors.
Item 1.01 verify on EDGAR → -
high
Gross proceeds of $5.5M (minus $125K in fees) will fund working capital and general corporate purposes, providing near-term operational runway for the biotech.
Item 1.01 verify on EDGAR → -
high
Warrant issuance requires shareholder approval before becoming exercisable; pre-funded warrants exercisable immediately at nominal price, representing near-term dilution.
Item 1.01 verify on EDGAR → -
medium
Proceeds will be received in three tranches closing May 27, June 15, and July 15, 2026, rather than as a lump sum, spreading capital infusion over two months.
Item 1.01 verify on EDGAR → -
medium
Placement agent Paulson receives 2% cash fee plus 117,647 ADSs (8% of offering), adding to total shareholder dilution from the transaction.
Item 1.01 verify on EDGAR →
Summary
Akari Therapeutics closed a $5.5 million private placement on May 20, 2026, selling 1.47 million ADSs at $3.74 per unit. Each unit includes one ADS (or pre-funded warrant) plus three series of warrants (H, I, and J), all exercisable at $3.74 per ADS. This structure creates substantial potential dilution—if all warrants are exercised, shareholders could see their ownership significantly reduced.
The pre-funded warrants are exercisable immediately at a nominal price, while the Series H, I, and J warrants require shareholder approval before becoming exercisable. For retail investors, this financing signals the company needed capital for operations but had to offer generous warrant coverage to attract buyers.
The $3.74 price point and warrant terms suggest investor caution about the company's near-term prospects. The staged closing schedule (three tranches through July 15) means the company receives funds incrementally rather than all at once. Watch for the shareholder vote on warrant issuance and monitor whether the company files a registration statement for resale of these securities. If warrants are exercised quickly after approval, it could pressure the stock price through dilution and selling by short-term investors.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Akari entered a $5.5M private placement selling 1.47M ADSs plus warrants at $3.74/unit, closing in three tranches through July 2026.
Added in current filing · verify on EDGAR →
On May 20, 2026, Akari Therapeutics, Plc (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors, pursuant to which the Company agreed to sell and issue in a private placement (the “Offering”) an aggregate of 1,470,588 unregistered American Depository Shares (“ADSs”), each representing 80,000 of the Company’s ordinary shares (the “Shares”), or prefunded warrants in lieu thereof (“Pre-Funded Warrants”), and, in each case, Series H warrants to purchase ADS (“Series H Warrants”), Series I warrants to purchase ADS (“Series I Warrants”) and Series J warrants to purchase ADS (“Series J Warrants”, together with the Pre-Funded Warrants, the Series H Warrants and the Series I Warrants, the “Warrants,” and together with the ADSs or Pre-Funded Warrants, the “Units”).
The company entered a securities purchase agreement to raise capital through a private placement. Each unit consists of one ADS (or pre-funded warrant) plus three series of warrants (H, I, and J), with each warrant allowing purchase of one additional ADS. The offering totals 1,470,588 units at $3.74 per ADS unit or $3.739 per pre-funded warrant unit.
Added in current filing · verify on EDGAR →
The issuance of the Series Warrants and the Placement Agent ADSs is subject to shareholder approval (“Shareholder Approval”). The Series Warrants will have an exercise price of $3.74 per ADS, and will be exercisable immediately when issued following the date of Shareholder Approval.
The Series H, I, and J warrants require shareholder approval before issuance and will have an exercise price of $3.74 per ADS. Once approved, these warrants become immediately exercisable, potentially adding significant dilution if exercised. The pre-funded warrants are exercisable immediately without shareholder approval.
Added in current filing · verify on EDGAR →
The gross proceeds of the Offering will be funded in three separate tranches pursuant to three separate closings, expected to occur on or about May 27, 2026, June 15, 2026 and July 15, 2026 (the “Third Closing Date”).
The financing will close in three tranches over approximately $3.74 two months, with closings expected around May 27, June 15, and July 15, 2026. This staged approach means the company will receive the capital incrementally rather than all at once.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Akari Therapeutics disclosed unregistered sales of equity securities, with details cross-referenced to Item 1.01.
Added in current filing · verify on EDGAR →
The information under Item 1.01 of this Current Report on Form 8-K regarding the unregistered securities described herein is incorporated herein by reference.
The company disclosed unregistered sales of equity securities under Item 3.02, but the substantive details are cross-referenced to Item 1.01 of the same 8-K filing. Without Item 1.01 content provided, the nature, amount, and terms of the equity issuance cannot be determined from this excerpt alone.
Event · Item 9.01 — Financial Statements and Exhibits
Akari Therapeutics executed a securities purchase agreement on May 20, 2026, issuing pre-funded warrants and three series of warrants.
Added in current filing · verify on EDGAR →
Form of Securities Purchase Agreement, dated May 20, 2026, by and among Akari Therapeutics, Plc and the purchasers party thereto
Akari Therapeutics entered into a securities purchase agreement on May 20, 2026 with multiple purchasers. This represents a capital-raising transaction, though the specific terms, pricing, and aggregate proceeds are not disclosed in this 8-K filing.
Added in current filing · verify on EDGAR →
Form of Pre-Funded Warrant
The company issued pre-funded warrants as part of the securities purchase agreement. Pre-funded warrants are typically exercisable immediately at a nominal price and represent near-term dilution to existing shareholders, though the number of warrants and exercise terms are not specified in this filing.
Added in current filing · verify on EDGAR →
Form of Series H Warrant
The company issued three separate series of warrants (Series H, Series I, and Series J) as part of the financing transaction. Multiple warrant series often have different exercise prices or expiration dates, creating potential future dilution at various price points, though specific terms are not disclosed in this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify